nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—MTOR—cervical cancer	0.851	1	CbGaD
Everolimus—CYP3A4—Topotecan—cervical cancer	0.0163	1	CbGbCtD
Everolimus—Acute respiratory distress syndrome—Topotecan—cervical cancer	0.00363	0.0895	CcSEcCtD
Everolimus—MTOR—epithelium—cervical cancer	0.00288	0.0641	CbGeAlD
Everolimus—Pimecrolimus—MTOR—cervical cancer	0.00272	0.349	CrCbGaD
Everolimus—MTOR—renal system—cervical cancer	0.00267	0.0594	CbGeAlD
Everolimus—FKBP1A—epithelium—cervical cancer	0.00259	0.0576	CbGeAlD
Everolimus—MTOR—endometrium—cervical cancer	0.00258	0.0574	CbGeAlD
Everolimus—FKBP1A—uterine cervix—cervical cancer	0.00257	0.0571	CbGeAlD
Everolimus—MTOR—mammalian vulva—cervical cancer	0.0025	0.0556	CbGeAlD
Everolimus—FKBP1A—decidua—cervical cancer	0.00245	0.0544	CbGeAlD
Everolimus—FKBP1A—renal system—cervical cancer	0.0024	0.0534	CbGeAlD
Everolimus—MTOR—uterus—cervical cancer	0.00238	0.0529	CbGeAlD
Everolimus—FKBP1A—endometrium—cervical cancer	0.00232	0.0517	CbGeAlD
Everolimus—FKBP1A—mammalian vulva—cervical cancer	0.00225	0.05	CbGeAlD
Everolimus—FKBP1A—uterus—cervical cancer	0.00214	0.0476	CbGeAlD
Everolimus—MTOR—female reproductive system—cervical cancer	0.00214	0.0476	CbGeAlD
Everolimus—MTOR—female gonad—cervical cancer	0.00195	0.0433	CbGeAlD
Everolimus—MTOR—vagina—cervical cancer	0.00194	0.043	CbGeAlD
Everolimus—FKBP1A—female reproductive system—cervical cancer	0.00193	0.0428	CbGeAlD
Everolimus—Temsirolimus—MTOR—cervical cancer	0.00184	0.236	CrCbGaD
Everolimus—MTOR—Interferon type I signaling pathways—PIAS3—cervical cancer	0.00182	0.0461	CbGpPWpGaD
Everolimus—FKBP1A—female gonad—cervical cancer	0.00175	0.0389	CbGeAlD
Everolimus—FKBP1A—vagina—cervical cancer	0.00174	0.0387	CbGeAlD
Everolimus—Mucosal inflammation—Topotecan—cervical cancer	0.00171	0.0422	CcSEcCtD
Everolimus—Tacrolimus—MTOR—cervical cancer	0.00162	0.208	CrCbGaD
Everolimus—Sirolimus—MTOR—cervical cancer	0.00162	0.208	CrCbGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—PIAS3—cervical cancer	0.00157	0.0397	CbGpPWpGaD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—WNT5A—cervical cancer	0.00145	0.0366	CbGpPWpGaD
Everolimus—Neuralgia—Topotecan—cervical cancer	0.00136	0.0336	CcSEcCtD
Everolimus—Interstitial lung disease—Topotecan—cervical cancer	0.00134	0.033	CcSEcCtD
Everolimus—MTOR—mTOR signaling pathway—YY1—cervical cancer	0.0013	0.0329	CbGpPWpGaD
Everolimus—MTOR—SREBP signalling—YY1—cervical cancer	0.00126	0.0317	CbGpPWpGaD
Everolimus—MTOR—lymph node—cervical cancer	0.00125	0.0278	CbGeAlD
Everolimus—Rash erythematous—Topotecan—cervical cancer	0.00124	0.0305	CcSEcCtD
Everolimus—Pleural effusion—Topotecan—cervical cancer	0.00124	0.0305	CcSEcCtD
Everolimus—FKBP1A—lymph node—cervical cancer	0.00113	0.025	CbGeAlD
Everolimus—Dysmenorrhoea—Topotecan—cervical cancer	0.00104	0.0257	CcSEcCtD
Everolimus—Blood bilirubin increased—Topotecan—cervical cancer	0.001	0.0247	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—UBE3A—cervical cancer	0.000977	0.0247	CbGpPWpGaD
Everolimus—Pulmonary embolism—Topotecan—cervical cancer	0.000947	0.0234	CcSEcCtD
Everolimus—MTOR—EGFR-dependent Endothelin signaling events—EGFR—cervical cancer	0.000867	0.0219	CbGpPWpGaD
Everolimus—Rash maculo-papular—Topotecan—cervical cancer	0.00086	0.0212	CcSEcCtD
Everolimus—Neoplasm—Topotecan—cervical cancer	0.000856	0.0211	CcSEcCtD
Everolimus—Sepsis—Topotecan—cervical cancer	0.000822	0.0203	CcSEcCtD
Everolimus—CYP3A4—renal system—cervical cancer	0.000786	0.0175	CbGeAlD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—PIAS3—cervical cancer	0.000757	0.0191	CbGpPWpGaD
Everolimus—FKBP1A—TOR Signaling—MTOR—cervical cancer	0.000724	0.0183	CbGpPWpGaD
Everolimus—Lethargy—Topotecan—cervical cancer	0.000701	0.0173	CcSEcCtD
Everolimus—Cardiac arrest—Topotecan—cervical cancer	0.000653	0.0161	CcSEcCtD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—WNT5A—cervical cancer	0.000635	0.016	CbGpPWpGaD
Everolimus—CYP3A4—female reproductive system—cervical cancer	0.000629	0.014	CbGeAlD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.00062	0.0157	CbGpPWpGaD
Everolimus—Aspartate aminotransferase increased—Topotecan—cervical cancer	0.000619	0.0153	CcSEcCtD
Everolimus—MTOR—IL2 signaling events mediated by PI3K—TERT—cervical cancer	0.000617	0.0156	CbGpPWpGaD
Everolimus—Alanine aminotransferase increased—Topotecan—cervical cancer	0.000606	0.015	CcSEcCtD
Everolimus—MTOR—Costimulation by the CD28 family—HLA-DPB1—cervical cancer	0.000584	0.0147	CbGpPWpGaD
Everolimus—Pancytopenia—Topotecan—cervical cancer	0.000564	0.0139	CcSEcCtD
Everolimus—Neutropenia—Topotecan—cervical cancer	0.000555	0.0137	CcSEcCtD
Everolimus—Pneumonia—Topotecan—cervical cancer	0.000533	0.0131	CcSEcCtD
Everolimus—Infestation—Topotecan—cervical cancer	0.00053	0.0131	CcSEcCtD
Everolimus—Infestation NOS—Topotecan—cervical cancer	0.00053	0.0131	CcSEcCtD
Everolimus—Stomatitis—Topotecan—cervical cancer	0.000516	0.0127	CcSEcCtD
Everolimus—Hepatobiliary disease—Topotecan—cervical cancer	0.000501	0.0124	CcSEcCtD
Everolimus—Epistaxis—Topotecan—cervical cancer	0.0005	0.0123	CcSEcCtD
Everolimus—FKBP1A—Role of Calcineurin-dependent NFAT signaling in lymphocytes—CASP3—cervical cancer	0.000481	0.0122	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta receptor signaling—CTNNB1—cervical cancer	0.000478	0.0121	CbGpPWpGaD
Everolimus—Haemoglobin—Topotecan—cervical cancer	0.000478	0.0118	CcSEcCtD
Everolimus—Rhinitis—Topotecan—cervical cancer	0.000477	0.0118	CcSEcCtD
Everolimus—Haemorrhage—Topotecan—cervical cancer	0.000475	0.0117	CcSEcCtD
Everolimus—Hypoaesthesia—Topotecan—cervical cancer	0.000473	0.0117	CcSEcCtD
Everolimus—Pharyngitis—Topotecan—cervical cancer	0.000472	0.0116	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—CD8A—cervical cancer	0.00047	0.0119	CbGpPWpGaD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—CTNNB1—cervical cancer	0.000464	0.0117	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—HLA-DQB1—cervical cancer	0.000456	0.0115	CbGpPWpGaD
Everolimus—MTOR—VEGFR2 mediated vascular permeability—CTNNB1—cervical cancer	0.000441	0.0112	CbGpPWpGaD
Everolimus—Angiopathy—Topotecan—cervical cancer	0.000431	0.0106	CcSEcCtD
Everolimus—Immune system disorder—Topotecan—cervical cancer	0.000429	0.0106	CcSEcCtD
Everolimus—Mediastinal disorder—Topotecan—cervical cancer	0.000428	0.0106	CcSEcCtD
Everolimus—Chills—Topotecan—cervical cancer	0.000427	0.0105	CcSEcCtD
Everolimus—Alopecia—Topotecan—cervical cancer	0.00042	0.0104	CcSEcCtD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—CTNNB1—cervical cancer	0.000418	0.0106	CbGpPWpGaD
Everolimus—Malnutrition—Topotecan—cervical cancer	0.000414	0.0102	CcSEcCtD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—STAT3—cervical cancer	0.000404	0.0102	CbGpPWpGaD
Everolimus—Back pain—Topotecan—cervical cancer	0.0004	0.00988	CcSEcCtD
Everolimus—Muscle spasms—Topotecan—cervical cancer	0.000398	0.00982	CcSEcCtD
Everolimus—Ill-defined disorder—Topotecan—cervical cancer	0.000384	0.00947	CcSEcCtD
Everolimus—Anaemia—Topotecan—cervical cancer	0.000383	0.00944	CcSEcCtD
Everolimus—MTOR—Regulation of Telomerase—TERT—cervical cancer	0.000379	0.00958	CbGpPWpGaD
Everolimus—Angioedema—Topotecan—cervical cancer	0.000378	0.00933	CcSEcCtD
Everolimus—Malaise—Topotecan—cervical cancer	0.000373	0.00921	CcSEcCtD
Everolimus—Leukopenia—Topotecan—cervical cancer	0.00037	0.00914	CcSEcCtD
Everolimus—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000368	0.0093	CbGpPWpGaD
Everolimus—Cough—Topotecan—cervical cancer	0.000361	0.00891	CcSEcCtD
Everolimus—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000354	0.00896	CbGpPWpGaD
Everolimus—Arthralgia—Topotecan—cervical cancer	0.000352	0.00869	CcSEcCtD
Everolimus—Myalgia—Topotecan—cervical cancer	0.000352	0.00869	CcSEcCtD
Everolimus—Chest pain—Topotecan—cervical cancer	0.000352	0.00869	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00035	0.00863	CcSEcCtD
Everolimus—Discomfort—Topotecan—cervical cancer	0.000348	0.00859	CcSEcCtD
Everolimus—MTOR—PI3K Cascade—FGFR3—cervical cancer	0.000348	0.00879	CbGpPWpGaD
Everolimus—Infection—Topotecan—cervical cancer	0.000336	0.00828	CcSEcCtD
Everolimus—Nervous system disorder—Topotecan—cervical cancer	0.000331	0.00817	CcSEcCtD
Everolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—EGFR—cervical cancer	0.000331	0.00836	CbGpPWpGaD
Everolimus—Thrombocytopenia—Topotecan—cervical cancer	0.000331	0.00816	CcSEcCtD
Everolimus—Skin disorder—Topotecan—cervical cancer	0.000328	0.00809	CcSEcCtD
Everolimus—Hyperhidrosis—Topotecan—cervical cancer	0.000327	0.00806	CcSEcCtD
Everolimus—Anorexia—Topotecan—cervical cancer	0.000322	0.00794	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—CA9—cervical cancer	0.000317	0.008	CbGpPWpGaD
Everolimus—Musculoskeletal discomfort—Topotecan—cervical cancer	0.000308	0.00759	CcSEcCtD
Everolimus—Paraesthesia—Topotecan—cervical cancer	0.000303	0.00748	CcSEcCtD
Everolimus—Dyspnoea—Topotecan—cervical cancer	0.000301	0.00743	CcSEcCtD
Everolimus—Dyspepsia—Topotecan—cervical cancer	0.000297	0.00734	CcSEcCtD
Everolimus—Decreased appetite—Topotecan—cervical cancer	0.000294	0.00724	CcSEcCtD
Everolimus—Gastrointestinal disorder—Topotecan—cervical cancer	0.000292	0.00719	CcSEcCtD
Everolimus—Fatigue—Topotecan—cervical cancer	0.000291	0.00718	CcSEcCtD
Everolimus—MTOR—IRS-mediated signalling—FGFR3—cervical cancer	0.000291	0.00736	CbGpPWpGaD
Everolimus—Constipation—Topotecan—cervical cancer	0.000289	0.00713	CcSEcCtD
Everolimus—Pain—Topotecan—cervical cancer	0.000289	0.00713	CcSEcCtD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FGFR3—cervical cancer	0.000288	0.00729	CbGpPWpGaD
Everolimus—MTOR—ErbB2/ErbB3 signaling events—STAT3—cervical cancer	0.000284	0.00717	CbGpPWpGaD
Everolimus—MTOR—IRS-related events—FGFR3—cervical cancer	0.000283	0.00715	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—FGFR3—cervical cancer	0.000281	0.00709	CbGpPWpGaD
Everolimus—Feeling abnormal—Topotecan—cervical cancer	0.000278	0.00687	CcSEcCtD
Everolimus—Gastrointestinal pain—Topotecan—cervical cancer	0.000276	0.00681	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—AKAP13—cervical cancer	0.000276	0.00698	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—FGFR3—cervical cancer	0.000273	0.0069	CbGpPWpGaD
Everolimus—MTOR—Insulin receptor signalling cascade—FGFR3—cervical cancer	0.000273	0.0069	CbGpPWpGaD
Everolimus—MTOR—IFN-gamma pathway—STAT3—cervical cancer	0.000273	0.0069	CbGpPWpGaD
Everolimus—MTOR—IL12-mediated signaling events—CD4—cervical cancer	0.00027	0.00683	CbGpPWpGaD
Everolimus—MTOR—Wnt Signaling Pathway Netpath—CTNNB1—cervical cancer	0.000269	0.0068	CbGpPWpGaD
Everolimus—Abdominal pain—Topotecan—cervical cancer	0.000267	0.00659	CcSEcCtD
Everolimus—Body temperature increased—Topotecan—cervical cancer	0.000267	0.00659	CcSEcCtD
Everolimus—MTOR—PI-3K cascade—FGFR3—cervical cancer	0.00026	0.00656	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—CASP3—cervical cancer	0.000258	0.00651	CbGpPWpGaD
Everolimus—MTOR—TSLP Signaling Pathway—STAT3—cervical cancer	0.000254	0.00642	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FGFR3—cervical cancer	0.000254	0.00641	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FGFR3—cervical cancer	0.000252	0.00636	CbGpPWpGaD
Everolimus—Hypersensitivity—Topotecan—cervical cancer	0.000249	0.00614	CcSEcCtD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FGFR3—cervical cancer	0.000246	0.00621	CbGpPWpGaD
Everolimus—MTOR—Costimulation by the CD28 family—CD4—cervical cancer	0.000244	0.00617	CbGpPWpGaD
Everolimus—Asthenia—Topotecan—cervical cancer	0.000242	0.00598	CcSEcCtD
Everolimus—Pruritus—Topotecan—cervical cancer	0.000239	0.0059	CcSEcCtD
Everolimus—MTOR—Oncostatin M Signaling Pathway—CASP3—cervical cancer	0.000233	0.0059	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	0.000232	0.00585	CbGpPWpGaD
Everolimus—Diarrhoea—Topotecan—cervical cancer	0.000231	0.0057	CcSEcCtD
Everolimus—MTOR—Interferon type I signaling pathways—STAT3—cervical cancer	0.000227	0.00575	CbGpPWpGaD
Everolimus—MTOR—Signaling by Insulin receptor—FGFR3—cervical cancer	0.000227	0.00574	CbGpPWpGaD
Everolimus—Dizziness—Topotecan—cervical cancer	0.000223	0.00551	CcSEcCtD
Everolimus—Vomiting—Topotecan—cervical cancer	0.000215	0.0053	CcSEcCtD
Everolimus—Rash—Topotecan—cervical cancer	0.000213	0.00525	CcSEcCtD
Everolimus—Dermatitis—Topotecan—cervical cancer	0.000213	0.00525	CcSEcCtD
Everolimus—MTOR—CDC42 signaling events—CTNNB1—cervical cancer	0.000212	0.00536	CbGpPWpGaD
Everolimus—Headache—Topotecan—cervical cancer	0.000212	0.00522	CcSEcCtD
Everolimus—MTOR—IL12-mediated signaling events—STAT3—cervical cancer	0.000209	0.00528	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—cervical cancer	0.000208	0.00526	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—EGFR—cervical cancer	0.000207	0.00523	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—CD4—cervical cancer	0.000206	0.00521	CbGpPWpGaD
Everolimus—Nausea—Topotecan—cervical cancer	0.000201	0.00495	CcSEcCtD
Everolimus—FKBP1A—Spinal Cord Injury—EGFR—cervical cancer	0.000197	0.00497	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—STAT3—cervical cancer	0.000196	0.00496	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FGFR3—cervical cancer	0.000194	0.00491	CbGpPWpGaD
Everolimus—MTOR—TSH signaling pathway—STAT3—cervical cancer	0.000194	0.0049	CbGpPWpGaD
Everolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—CTNNB1—cervical cancer	0.000191	0.00482	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FGFR3—cervical cancer	0.000186	0.00469	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—CTNNB1—cervical cancer	0.000183	0.00463	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FGFR3—cervical cancer	0.000183	0.00462	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	0.000175	0.00443	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—STAT3—cervical cancer	0.000175	0.00442	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FGFR3—cervical cancer	0.000175	0.00441	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FGFR3—cervical cancer	0.000174	0.00439	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—cervical cancer	0.000174	0.00439	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FGFR3—cervical cancer	0.000173	0.00437	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FGFR3—cervical cancer	0.000172	0.00435	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—EGFR—cervical cancer	0.000172	0.00435	CbGpPWpGaD
Everolimus—FKBP1A—Disease—WNT2—cervical cancer	0.000171	0.00433	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—UBE3A—cervical cancer	0.00017	0.00429	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FGFR3—cervical cancer	0.00017	0.00429	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	0.000169	0.00427	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—cervical cancer	0.000165	0.00417	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FGFR3—cervical cancer	0.000162	0.00409	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FGFR3—cervical cancer	0.000162	0.00409	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FGFR3—cervical cancer	0.000162	0.00409	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FGFR3—cervical cancer	0.00016	0.00405	CbGpPWpGaD
Everolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—STAT3—cervical cancer	0.00016	0.00404	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—STAT3—cervical cancer	0.00016	0.00404	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FGFR3—cervical cancer	0.000159	0.00402	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FGFR3—cervical cancer	0.000158	0.004	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP8—cervical cancer	0.000157	0.00397	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TAAR6—cervical cancer	0.000154	0.00389	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—CTNNB1—cervical cancer	0.000151	0.00382	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FGFR3—cervical cancer	0.00015	0.00379	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—cervical cancer	0.00015	0.00378	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FGFR3—cervical cancer	0.000143	0.00362	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—cervical cancer	0.000143	0.00361	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—CTNNB1—cervical cancer	0.000143	0.0036	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—EGFR—cervical cancer	0.000142	0.0036	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	0.000134	0.00338	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—STAT3—cervical cancer	0.000134	0.00338	CbGpPWpGaD
Everolimus—FKBP1A—Disease—WNT5A—cervical cancer	0.00013	0.00328	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—EGFR—cervical cancer	0.000128	0.00324	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—EGFR—cervical cancer	0.000125	0.00317	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—EGFR—cervical cancer	0.000124	0.00314	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—CASP3—cervical cancer	0.000124	0.00312	CbGpPWpGaD
Everolimus—MTOR—ErbB1 downstream signaling—EGFR—cervical cancer	0.000121	0.00307	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—cervical cancer	0.000121	0.00307	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—WNT2—cervical cancer	0.00012	0.00303	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—CTNNB1—cervical cancer	0.000119	0.00301	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CASP3—cervical cancer	0.000119	0.00301	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—CTNNB1—cervical cancer	0.000115	0.0029	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	0.000112	0.00284	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FGFR3—cervical cancer	0.00011	0.00279	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—STAT3—cervical cancer	0.000106	0.00267	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—AKAP13—cervical cancer	0.000105	0.00266	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—STAT3—cervical cancer	0.000104	0.00262	CbGpPWpGaD
Everolimus—MTOR—Immune System—UBE3A—cervical cancer	0.000103	0.0026	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—cervical cancer	0.000102	0.00258	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DPB1—cervical cancer	0.000101	0.00256	CbGpPWpGaD
Everolimus—MTOR—Disease—WNT2—cervical cancer	9.64e-05	0.00244	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—EGFR—cervical cancer	9.59e-05	0.00242	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—STAT3—cervical cancer	9.49e-05	0.0024	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—STAT3—cervical cancer	9.45e-05	0.00239	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—EGFR—cervical cancer	9.18e-05	0.00232	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—WNT5A—cervical cancer	9.1e-05	0.0023	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—EGFR—cervical cancer	9.08e-05	0.0023	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—EGFR—cervical cancer	9.03e-05	0.00228	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—STAT3—cervical cancer	8.8e-05	0.00222	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TAAR6—cervical cancer	8.65e-05	0.00219	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—EGFR—cervical cancer	8.63e-05	0.00218	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—STAT3—cervical cancer	8.61e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—EGFR—cervical cancer	8.58e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—EGFR—cervical cancer	8.58e-05	0.00217	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—EGFR—cervical cancer	8.54e-05	0.00216	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—EGFR—cervical cancer	8.5e-05	0.00215	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—EGFR—cervical cancer	8.38e-05	0.00212	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—EGFR—cervical cancer	8e-05	0.00202	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—EGFR—cervical cancer	8e-05	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—EGFR—cervical cancer	8e-05	0.00202	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—EGFR—cervical cancer	7.93e-05	0.002	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—HLA-DQB1—cervical cancer	7.91e-05	0.002	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—EGFR—cervical cancer	7.86e-05	0.00199	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—EGFR—cervical cancer	7.82e-05	0.00198	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—STAT3—cervical cancer	7.79e-05	0.00197	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—cervical cancer	7.63e-05	0.00193	CbGpPWpGaD
Everolimus—FKBP1A—Disease—HES1—cervical cancer	7.48e-05	0.00189	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—EGFR—cervical cancer	7.4e-05	0.00187	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD8A—cervical cancer	7.38e-05	0.00187	CbGpPWpGaD
Everolimus—MTOR—Disease—WNT5A—cervical cancer	7.31e-05	0.00185	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—CASP3—cervical cancer	7.13e-05	0.0018	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—EGFR—cervical cancer	7.08e-05	0.00179	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WNT2—cervical cancer	6.75e-05	0.00171	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTHFR—cervical cancer	6.57e-05	0.00166	CbGpPWpGaD
Everolimus—FKBP1A—Disease—TERT—cervical cancer	6.55e-05	0.00166	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—STAT3—cervical cancer	6.39e-05	0.00162	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH2—cervical cancer	6.39e-05	0.00161	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—FGFR3—cervical cancer	6.29e-05	0.00159	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DPB1—cervical cancer	6.14e-05	0.00155	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—FGFR3—cervical cancer	6.04e-05	0.00153	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FGFR3—cervical cancer	6.01e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—STAT3—cervical cancer	5.99e-05	0.00152	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—AKAP13—cervical cancer	5.93e-05	0.0015	CbGpPWpGaD
Everolimus—FKBP1A—Disease—NOTCH1—cervical cancer	5.65e-05	0.00143	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—EGFR—cervical cancer	5.45e-05	0.00138	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CASP8—cervical cancer	5.38e-05	0.00136	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—HES1—cervical cancer	5.24e-05	0.00132	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—WNT5A—cervical cancer	5.12e-05	0.00129	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—TP53—cervical cancer	4.88e-05	0.00123	CbGpPWpGaD
Everolimus—MTOR—Immune System—HLA-DQB1—cervical cancer	4.8e-05	0.00121	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TERT—cervical cancer	4.59e-05	0.00116	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD8A—cervical cancer	4.48e-05	0.00113	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CD4—cervical cancer	4.42e-05	0.00112	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD4—cervical cancer	4.24e-05	0.00107	CbGpPWpGaD
Everolimus—FKBP1A—Disease—MTOR—cervical cancer	4.23e-05	0.00107	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CD4—cervical cancer	4.22e-05	0.00107	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—FGFR3—cervical cancer	4.21e-05	0.00106	CbGpPWpGaD
Everolimus—MTOR—Disease—HES1—cervical cancer	4.21e-05	0.00106	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—NOTCH1—cervical cancer	3.95e-05	0.000999	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—CTNNB1—cervical cancer	3.92e-05	0.000991	CbGpPWpGaD
Everolimus—FKBP1A—Disease—CTNNB1—cervical cancer	3.75e-05	0.000948	CbGpPWpGaD
Everolimus—MTOR—Disease—MTHFR—cervical cancer	3.7e-05	0.000934	CbGpPWpGaD
Everolimus—MTOR—Disease—TERT—cervical cancer	3.69e-05	0.000931	CbGpPWpGaD
Everolimus—MTOR—Immune System—FGFR3—cervical cancer	3.66e-05	0.000926	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH2—cervical cancer	3.59e-05	0.000908	CbGpPWpGaD
Everolimus—MTOR—Disease—FGFR3—cervical cancer	3.38e-05	0.000855	CbGpPWpGaD
Everolimus—FKBP1A—Disease—STAT3—cervical cancer	3.27e-05	0.000826	CbGpPWpGaD
Everolimus—MTOR—Disease—NOTCH1—cervical cancer	3.18e-05	0.000802	CbGpPWpGaD
Everolimus—MTOR—Immune System—CASP8—cervical cancer	3.13e-05	0.000792	CbGpPWpGaD
Everolimus—MTOR—Innate Immune System—EGFR—cervical cancer	3.11e-05	0.000785	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—EGFR—cervical cancer	2.98e-05	0.000754	CbGpPWpGaD
Everolimus—FKBP1A—Disease—EGFR—cervical cancer	2.97e-05	0.000751	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MTOR—cervical cancer	2.96e-05	0.000749	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—HES1—cervical cancer	2.95e-05	0.000744	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CASP3—cervical cancer	2.72e-05	0.000689	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—CTNNB1—cervical cancer	2.63e-05	0.000664	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TERT—cervical cancer	2.58e-05	0.000652	CbGpPWpGaD
Everolimus—MTOR—Immune System—CD4—cervical cancer	2.57e-05	0.00065	CbGpPWpGaD
Everolimus—MTOR—Disease—CD4—cervical cancer	2.37e-05	0.0006	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FGFR3—cervical cancer	2.37e-05	0.000599	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—STAT3—cervical cancer	2.29e-05	0.000579	CbGpPWpGaD
Everolimus—MTOR—Immune System—CTNNB1—cervical cancer	2.28e-05	0.000577	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—NOTCH1—cervical cancer	2.22e-05	0.000562	CbGpPWpGaD
Everolimus—MTOR—Disease—CTNNB1—cervical cancer	2.11e-05	0.000533	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—EGFR—cervical cancer	2.08e-05	0.000526	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—CA9—cervical cancer	2.02e-05	0.000511	CbGpPWpGaD
Everolimus—MTOR—Immune System—STAT3—cervical cancer	1.99e-05	0.000503	CbGpPWpGaD
Everolimus—MTOR—Disease—STAT3—cervical cancer	1.84e-05	0.000465	CbGpPWpGaD
Everolimus—MTOR—Immune System—EGFR—cervical cancer	1.81e-05	0.000457	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—cervical cancer	1.75e-05	0.000442	CbGpPWpGaD
Everolimus—MTOR—Disease—EGFR—cervical cancer	1.67e-05	0.000422	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CASP3—cervical cancer	1.53e-05	0.000387	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—CTNNB1—cervical cancer	1.48e-05	0.000373	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—STAT3—cervical cancer	1.29e-05	0.000325	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—EGFR—cervical cancer	1.17e-05	0.000296	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—cervical cancer	9.83e-06	0.000248	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MTHFR—cervical cancer	8.21e-06	0.000207	CbGpPWpGaD
